老年高血压患者应用厄贝沙坦氢氯噻嗪片联合苯磺酸氨氯地平片治疗的临床效果观察  

Observation on clinical effect of irbesartan and hydrochlorothiazide tablets combined with amlodipine besylate tablets in the treatment of elderly patients with hypertension

作　　者：肖宁 张鑫 XIAO Ning;ZHANG Xin(Department of Cardiology,Yanggu County People's Hospital,Liaocheng 252300,China)

机构地区：[1]阳谷县人民医院心内科一区,252300 [2]阳谷县人民医院心电图室,252300

出　　处：《中国现代药物应用》2023年第19期18-21,共4页Chinese Journal of Modern Drug Application

摘　　要：目的 探究厄贝沙坦氢氯噻嗪片联合苯磺酸氨氯地平片治疗老年高血压患者的效果。方法 100例老年高血压患者,经随机数字表法分为对照组和观察组,每组50例。对照组采用厄贝沙坦氢氯噻嗪片治疗,观察组实施厄贝沙坦氢氯噻嗪片联合苯磺酸氨氯地平片治疗。比较两组患者治疗效果,治疗前后血压水平、生化指标水平及不良反应发生情况。结果 观察组治疗总有效率为96.00%(48/50),明显高于对照组的84.00%(42/50),差异具有统计学意义(P<0.05)。治疗前,两组患者收缩压(SBP)、舒张压(DBP)水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者SBP、DBP水平均明显低于本组治疗前,且观察组SBP、DBP水平分别为(123.21±9.89)、(80.21±4.87)mm Hg(1 mm Hg=0.133 kPa),均明显低于对照组的(142.89±10.11)、(94.89±5.89)mm Hg,差异有统计学意义(P<0.05)。治疗前,两组患者尿素氮和尿微量白蛋白水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者的尿素氮和尿微量白蛋白水平均明显低于本组治疗前,且观察组尿素氮和尿微量白蛋白水平分别为(8.33±0.70)mmol/L、(48.68±3.03)mg/L,明显低于对照组的(9.48±0.39)mmol/L、(53.27±2.99)mg/L,差异有统计学意义(P<0.05)。观察组不良反应发生率为8.00%,与对照组的6.00%比较,差异无统计学意义(P>0.05)。结论 厄贝沙坦氢氯噻嗪片联合苯磺酸氨氯地平片治疗老年高血压患者的效果显著,可改善患者血压水平,并纠正生化指标水平,值得推广应用。Objective To investigate the effect of irbesartan and hydrochlorothiazide tablets combined with amlodipine besylate tablets in the treatment of elderly patients with hypertension.Methods A total of 100 elderly patients with hypertension were divided into control group and observation group according to random numerical table,with 50 cases in each group.The control group was treated with irbesartan and hydrochlorothiazide tablets,and the observation group was treated with irbesartan and hydrochlorothiazide tablets and amlodipine besylate tablets.The therapeutic effect,blood pressure level and biochemical index level before and after treatment,and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 96.00%(48/50),which was significantly higher than that of 84.00%(42/50)of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in systolic blood pressure(SBP)and diastolic blood pressure(DBP)between the two groups(P>0.05).After treatment,the levels of SBP and DBP in both groups were significantly lower than those before treatment in this group;the levels of SBP and DBP in the observation group were(123.21±9.89)and(80.21±4.87)mm Hg(1 mm Hg=0.133 kPa),which were significantly lower than those of(142.89±10.11)and(94.89±5.89)mm Hg in the control group;the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of urea nitrogen and urinary microalbumin between the two groups(P>0.05).After treatment,the levels of urea nitrogen and urinary microalbumin in both groups were significantly lower than those before treatment in this group;the levels of urea nitrogen and urinary microalbumin in the observation group were(8.33±0.70)mmol/L and(48.68±3.03)mg/L,which were significantly lower than those of(9.48±0.39)mmol/L and(53.27±2.99)mg/L in the control group;the differences were stat

关 键 词：老年高血压 厄贝沙坦氢氯噻嗪片 苯磺酸氨氯地平片 生化指标 安全性 

分 类 号：R544.1[医药卫生—心血管疾病]